Literature DB >> 19759551

Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

Braslav Jovanovic, Suzanne Egyhazi, Malihe Eskandarpour, Paola Ghiorzo, Jane M Palmer, Giovanna Bianchi Scarrà, Nicholas K Hayward, Johan Hansson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19759551      PMCID： PMC3665509          DOI： 10.1038/jid.2009.287

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  23 in total

1.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Authors:  Esther Edlundh-Rose; Suzanne Egyházi; Katarina Omholt; Eva Månsson-Brahme; Anton Platz; Johan Hansson; Joakim Lundeberg
Journal:  Melanoma Res       Date:  2006-12       Impact factor: 3.599

2.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

3.  Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Authors:  Katarina Omholt; Sofia Karsberg; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

4.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

5.  Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Authors:  Malihe Eskandarpour; Jamileh Hashemi; Lena Kanter; Ulrik Ringborg; Anton Platz; Johan Hansson
Journal:  J Natl Cancer Inst       Date:  2003-06-04       Impact factor: 13.506

6.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

7.  Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.

Authors:  Braslav Jovanovic; Doris Kröckel; Diana Linden; Bo Nilsson; Suzanne Egyhazi; Johan Hansson
Journal:  J Invest Dermatol       Date:  2008-05-29       Impact factor: 8.551

8.  Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Robert C Millikan; Pamela A Groben; Honglin Hao; Dawn Tolbert; Marianne Berwick; Klaus Busam; Colin B Begg; Dianne Mattingly; David W Ollila; Chiu Kit Tse; Amanda Hummer; Julia Lee-Taylor; Kathleen Conway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26
View more
  18 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

2.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 3.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

Review 4.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

5.  Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Authors:  Yingmei Wang; Da Yang; David Cogdell; Limei Hu; Fengxia Xue; Russell Broaddus; Wei Zhang
Journal:  Technol Cancer Res Treat       Date:  2010-04

6.  Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.

Authors:  Vito W Rebecca; Keiran Sm Smalley
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

Review 7.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

8.  Histologic features of melanoma associated with CDKN2A genotype.

Authors:  Michael R Sargen; Peter A Kanetsky; Julia Newton-Bishop; Nicholas K Hayward; Graham J Mann; Nelleke A Gruis; Margaret A Tucker; Alisa M Goldstein; Giovanna Bianchi-Scarra; Susana Puig; David E Elder
Journal:  J Am Acad Dermatol       Date:  2015-01-13       Impact factor: 11.527

9.  Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Authors:  Juliette Delaunay; Ludovic Martin; Brigitte Bressac-de Paillerets; Gerard Duru; Olivier Ingster; Luc Thomas
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

Review 10.  NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Authors:  I V Fedorenko; G T Gibney; K S M Smalley
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.